AptarGroup’s Unidose Powder Nasal Delivery System was deployed in the Phase II clinical study of ENA Respiratory’s investigational nasal spray, INNA‑051, beginning on March 19 2026. The study will assess the safety and efficacy of the virus‑agnostic spray, which is designed to activate local innate immune defenses and reduce the impact of symptomatic viral respiratory infections.
The collaboration underscores Aptar’s strategy of innovation‑led growth. The Unidose platform, which delivers dry powder directly to the nasal cavity, has proven versatile across multiple therapeutic areas. By partnering with ENA Respiratory, Aptar expands its presence in the rapidly growing virus‑protection market, a segment that is expected to grow as demand for non‑vaccine respiratory solutions rises.
Aptar’s financial performance in the most recent quarter supports the strategic value of this partnership. In Q4 2025, the company reported adjusted earnings per share of $1.25, beating the consensus estimate of $1.24, and revenue of $962.74 million, surpassing the $878.58 million forecast. Sales grew 5% year‑over‑year, while core sales increased 2%. Adjusted EBITDA margin fell to 19.8% from 23.0% in the prior year, a decline attributed to a shift in product mix and higher production costs. For the full year 2025, earnings per share rose 7% to $5.89, and revenue increased 5% to $4.02 billion.
Management highlighted the partnership’s significance. Alex Theodorakis, President of Aptar Pharma Prescription, said, "Aptar Pharma is proud to support ENA Respiratory in the clinical development of INNA‑051 through the use of our UDS powder nasal delivery system." The quote reflects Aptar’s confidence in the technology and its potential to generate new revenue streams within the pharmaceutical segment, which accounts for more than two‑thirds of the company’s profits.
Looking ahead, Aptar has guided for Q1 2026 earnings per share of $1.13 to $1.21, indicating continued confidence in its operating performance. The company’s focus on expanding its drug‑delivery portfolio, combined with the promising early data from the INNA‑051 study, positions it to capture a share of the growing market for non‑vaccine respiratory protection solutions.
The partnership with ENA Respiratory represents a key operational milestone for Aptar, reinforcing its commitment to delivering innovative delivery technologies and expanding its footprint in high‑growth therapeutic areas. The collaboration is expected to enhance Aptar’s competitive positioning and contribute to future revenue growth in the pharmaceutical segment.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.